2019 Tuberculosis Drug Discovery and Development GRC: Shortening the Duration of Tuberculosis Chemotherapy and GRS

2019结核病药物发现与开发GRC：缩短结核病化疗和GRS的持续时间

• 批准号: 9750348
• 负责人: Mary Jackson
• 金额: $ 0.6万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-06-04 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9750348
• 关键词: Academia; Address; Adherence; Bacteria; Cause of Death; Chemistry; Clinic; Clinical Research; Clinical Trials; Collaborations; Communities; Disease; Drug Transport; Drug resistance; Elements; Ensure; Environment; Epidemic; Evaluation; Face; Fostering; Future; Goals; Growth; Hour; Industry; Infection; Infectious Agent; International; Medicine; Microbiology; Outcome; Participant; Patients; Performance; Pharmaceutical Preparations; Pharmacology; Property; Public Health; Publishing; Regimen; Research; Research Personnel; Safety; Science; Scientist; Site; Spain; Treatment Protocols; Tuberculosis; Underrepresented Minority; Update; Woman; Work; base; bench to bedside; career; career development; chemotherapy; collaborative environment; combat; data exchange; design; drug development; drug discovery; meetings; preclinical development; programs; research clinical testing; symposium; treatment duration; tuberculosis chemotherapy; tuberculosis drugs

Abstract This application seeks partial support for the 2019 Tuberculosis (TB) Drug Discovery & Development Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held in at the Rey Don Jaime Grand Hotel in Castelldefels, Spain from July 6-7 and 7-12, 2019. This will be the tenth GRC on TB Drug discovery with the first being held in 2001 and thereafter on a biennial basis and the fourth GRS associated with this GRC. This is the most important global conference on tuberculosis drug discovery and has consistently received a high-performance rating in the GRC Conference Evaluation outcome with more than 70% of conferees rating this meeting above average over the years. This GRC brings together TB drug development researchers from academia and industry in a friendly highly interactive environment to focus on the challenge of combatting this global public health threat. TB is now the leading cause of death internationally due to a single infectious agent despite the availability of a 6-9 month treatment regimen that achieves ~83% cure rates. This GRC has been assembled around the concept that the WHO's strategy to end the global TB epidemic can only be achieved by developing regimens with dramatically reduced treatment durations. A shorter treatment duration with drugs of similar of preferably increased safety profiles will lead to better adherence and importantly, combat the emerging threat of drug resistance. Under the theme of treatment shortening, this conference will bring together investigators with diverse backgrounds, including microbiology, chemistry, pharmacology, medicine and clinical research. The sessions have been orchestrated to provide a bench-to-bedside view of critical elements in achieving treatment shortening in the TB drug discovery field. The GRC will provide a unique opportunity to bring together the world's leading TB drug discovery researchers as well as a few researchers from outside the field who are doing work that may have a fundamental impact of how TB drug discovery may be approached in the future. The GRC and associated GRS foster an environment wherein which researchers are encouraged to share cutting edge unpublished data and exchange ideas between both established as well as young investigators and trainees hereby promoting career development for all attendees. The GRC will include a “Power Hour”, an optional informal gathering for all meeting participants to address the challenges women face in science and to support the professional growth of women in science. Both the GRC and the GRS programs will reflect the diversity of the scientists in the field with an aim of strong representation of women, underrepresented minorities and international scientists.

抽象的 该申请寻求部分支持2019年结核病（TB）药物发现与开发Gordon 研究会议（GRC）和戈登研究研讨会（GRS）将在Rey Don Jaime Grand举行 2019年7月6日至7日和7-12日在西班牙卡斯特尔德夫人的酒店。 这将是结核病药物发现的第十个GRC，并于2001年首次举行，此后两年一次 基础和与此GRC相关的第四个gr。这是最重要的全球会议 结核病药物发现，并在GRC会议上始终获得高性能评级 评估结果超过70％的会议多年来将这次会议评级为高于平均水平。这 GRC将来自学术界和行业的结核病药物开发研究人员汇集在一起 互动环境专注于应对这一全球公共卫生威胁的挑战。 TB现在是 由于单一传染代理目的地，国际上的主要死亡原因是6-9个月的可用性 达到约83％的治疗率的治疗方案。这个GRC是围绕这个概念组成的 谁能结束全球结核病流行的策略，只能通过急剧开发方案来实现 减少治疗持续时间。优先提高安全性相似的药物的治疗时间较短 剖面将导致更好的依从性，重要的是，应对新兴的耐药性威胁。 在治疗缩短的主题下，这次会议将与潜水 背景，包括微生物学，化学，药理学，医学和临床研究。会议 已精心策划，为实现治疗的关键要素提供基准对卧式的视图 结核病药物发现领域的缩短。 GRC将提供一个独特的机会，将 世界领先的结核病药物发现研究人员以及来自该领域以外的一些研究人员 做可能会对未来如何进行结核病药物发现具有根本影响的工作。 GRC和相关的GRS促进了一个鼓励研究人员分享的环境 尖端的数据和未发表的数据和既定的年轻调查员之间的交换想法 和受训者在此促进所有与会者的职业发展。 GRC将包括一个“力量时光”，一个 所有会议参与者的可选非正式聚会，以应对女性在科学领域面临的挑战和 支持妇女在科学领域的专业成长。 GRC和GRS程序都将反映 该领域的科学家的多样性，目的是对妇女的强烈代表，代表人数不足 少数民族和国际科学家。